Evolution of the Average Target: BioNTech SE

Evolution of the Average Target - BioNTech SE

Evolution of the Target Price: BioNTech SE

Evolution of the Target Price - BioNTech SE

Changes in Analyst Recommendations: BioNTech SE

b7a74adf46b4f1adc6d3.s1IvWs5PDjdgIFn7bV93ulxF7b-pZozsf__Jvhm25rQ._mUfMY98ZGAyFwazHxAF9C4Bpdn-LtOOS7eH123SqfuEKkBppjU_byETCA~835b4a9e67ddf5af3317ef52229a7ca8
27/10 BioNTech SE : UBS reiterates its Buy rating ZD
10/10 BofA Adjusts Price Target on BioNTech to $114 From $122, Keeps Buy Rating MT
08/10 Argus Research Initiates Coverage on BioNTech SE With Hold Rating MT
07/10 BioNTech SE : Gets a Buy rating from Berenberg ZD
16/09 Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating MT
16/09 BioNTech SE : UBS maintains a Buy rating ZD
16/09 BioNTech SE : Jefferies keeps its Buy rating ZD
16/09 BioNTech SE : Berenberg gives a Buy rating ZD
16/09 BioNTech SE : Jefferies maintains a Buy rating ZD
08/09 BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128 MT
04/09 BioNTech SE : Goldman Sachs gives a Buy rating ZD
29/08 Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial MT
26/08 BioNTech SE : Deutsche Bank reiterates its Buy rating ZD
20/08 Cancer vaccines finally garner the spotlight Alphavalue
20/08 BioNTech SE : Jefferies keeps its Buy rating ZD
05/08 Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating MT
05/08 BIONTECH : Berenberg reiterates its Buy rating ZD
05/08 BIONTECH : Gets a Buy rating from Jefferies ZD
05/08 BIONTECH : Bernstein sticks Neutral ZD
05/08 BioNTech: Q2 miss, followed by a sales guidance downgrade Alphavalue
04/08 Wall Street Bets on the Magnificent Seven Again Zonebourse
15/07 Where would AI lead Pharma in the long run? Alphavalue
08/07 Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating MT
01/06 BIONTECH : Buy rating from Jefferies ZD
28/05 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+32.42%
+32.59%
+28.07%
+10.26%
+8.34%
+15.58%
+38.17%
+38.53%
+31.23%
+4.99%
Average +24.02%
Weighted average by Cap. +23.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
77.67EUR
Average target price
104.13EUR
Spread / Average Target
+34.07%
High Price Target
128.59EUR
Spread / Highest target
+65.56%
Low Price Target
67.87EUR
Spread / Lowest Target
-12.62%

Analyst Consensus Detail

Analyst consensus - BioNTech SE

Consensus revision (last 18 months)

Consensus revision (last 18 months) - BioNTech SE
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock
  4. Consensus BioNTech SE